Furthermore, the estimated effect of SGLT2 inhibition on prostate cancer could at least in part be influenced by different ancestries, disease status, and survival bias, given the relatively late age-at-onset of prostate cancer. The gene discussed is SLC5A2; the disease is prostate carcinoma.